BACKGROUND: Whereas the frequency of alopecia to cytotoxic chemotherapies has been well described, the incidence of alopecia during endocrine therapies (i.e., anti-estrogens, aromatase inhibitors) has not been investigated. Endocrine agents are widely used in the treatment and prevention of many solid tumors, principally those of the breast and prostate. Adherence to these therapies is suboptimal, in part because of toxicities. We performed a systematic analysis of the literature to ascertain the incidence and risk for alopecia in patients receiving endocrine therapies. METHODS: An independent search of citations was conducted using the PubMed database for all literature as of February 2013. Phase II-III studies using the terms "tamoxifen," "toremifene," "raloxifene," "anastrozole," "letrozole," "exemestane," "fulvestrant," "leuprolide," "flutamide," "bicalutamide," "nilutamide," "fluoxymesterone," "estradiol," "octreotide," "megestrol," "medroxyprogesterone acetate," "enzalutamide," and "abiraterone" were searched. RESULTS: Data from 19,430 patients in 35 clinical trials were available for analysis. Of these, 13,415 patients had received endocrine treatments and 6,015 patients served as controls. The incidence of all-grade alopecia ranged from 0% to 25%, with an overall incidence of 4.4% (95% confidence interval: 3.3%-5.9%). The highest incidence of all-grade alopecia was observed in patients treated with tamoxifen in a phase II trial (25.4%); similarly, the overall incidence of grade 2 alopecia by meta-analysis was highest with tamoxifen (6.4%). The overall relative risk of alopecia in comparison with placebo was 12.88 (p < .001), with selective estrogen receptor modulators having the highest risk. CONCLUSION: Alopecia is a common yet underreported adverse event of endocrine-based cancer therapies. Their long-term use heightens the importance of this condition on patients' quality of life. These findings are critical for pretherapy counseling, the identification of risk factors, and the development of interventions that could enhance adherence and mitigate this psychosocially difficult event.
BACKGROUND: Whereas the frequency of alopecia to cytotoxic chemotherapies has been well described, the incidence of alopecia during endocrine therapies (i.e., anti-estrogens, aromatase inhibitors) has not been investigated. Endocrine agents are widely used in the treatment and prevention of many solid tumors, principally those of the breast and prostate. Adherence to these therapies is suboptimal, in part because of toxicities. We performed a systematic analysis of the literature to ascertain the incidence and risk for alopecia in patients receiving endocrine therapies. METHODS: An independent search of citations was conducted using the PubMed database for all literature as of February 2013. Phase II-III studies using the terms "tamoxifen," "toremifene," "raloxifene," "anastrozole," "letrozole," "exemestane," "fulvestrant," "leuprolide," "flutamide," "bicalutamide," "nilutamide," "fluoxymesterone," "estradiol," "octreotide," "megestrol," "medroxyprogesterone acetate," "enzalutamide," and "abiraterone" were searched. RESULTS: Data from 19,430 patients in 35 clinical trials were available for analysis. Of these, 13,415 patients had received endocrine treatments and 6,015 patients served as controls. The incidence of all-grade alopecia ranged from 0% to 25%, with an overall incidence of 4.4% (95% confidence interval: 3.3%-5.9%). The highest incidence of all-grade alopecia was observed in patients treated with tamoxifen in a phase II trial (25.4%); similarly, the overall incidence of grade 2 alopecia by meta-analysis was highest with tamoxifen (6.4%). The overall relative risk of alopecia in comparison with placebo was 12.88 (p < .001), with selective estrogen receptor modulators having the highest risk. CONCLUSION: Alopecia is a common yet underreported adverse event of endocrine-based cancer therapies. Their long-term use heightens the importance of this condition on patients' quality of life. These findings are critical for pretherapy counseling, the identification of risk factors, and the development of interventions that could enhance adherence and mitigate this psychosocially difficult event.
Authors: P E Lønning; E Bajetta; R Murray; M Tubiana-Hulin; P D Eisenberg; E Mickiewicz; L Celio; P Pitt; M Mita; N K Aaronson; C Fowst; A Arkhipov; E di Salle; A Polli; G Massimini Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: Raimund Jakesz; Hubert Hausmaninger; Ernst Kubista; Michael Gnant; Christian Menzel; Thomas Bauernhofer; Michael Seifert; Karin Haider; Brigitte Mlineritsch; Peter Steindorfer; Werner Kwasny; Michael Fridrik; Guenther Steger; Viktor Wette; Hellmut Samonigg Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: R A Nesbit; R L Woods; M H Tattersall; R M Fox; J F Forbes; I R MacKay; M Goodyear Journal: N Engl J Med Date: 1979-11-29 Impact factor: 91.245
Authors: A Buzdar; J Douma; N Davidson; R Elledge; M Morgan; R Smith; L Porter; J Nabholtz; X Xiang; C Brady Journal: J Clin Oncol Date: 2001-07-15 Impact factor: 44.544
Authors: James V Fiorica; Virginia L Brunetto; Parviz Hanjani; Samuel S Lentz; Robert Mannel; Willie Andersen Journal: Gynecol Oncol Date: 2004-01 Impact factor: 5.482
Authors: Vincent Sibaud; Nicole R Lebœuf; Henri Roche; Viswanath R Belum; Laurence Gladieff; Marion Deslandres; Marion Montastruc; Audrey Eche; Emmanuelle Vigarios; Florence Dalenc; Mario E Lacouture Journal: Eur J Dermatol Date: 2016-10-01 Impact factor: 3.328
Authors: Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture Journal: Breast Cancer Res Treat Date: 2018-11-22 Impact factor: 4.872
Authors: Azael Freites-Martinez; Jerry Shapiro; Corina van den Hurk; Shari Goldfarb; Joaquin J Jimenez; Anthony M Rossi; Ralf Paus; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2018-04-14 Impact factor: 11.527
Authors: Martina Silvestri; Antonio Cristaudo; Aldo Morrone; Claudia Messina; Luigi Bennardo; Steven Paul Nisticò; Maria Mariano; Norma Cameli Journal: Drug Saf Date: 2021-05-06 Impact factor: 5.606